Century Therapeutics Advances Diabetes Cell Therapy Toward 2026 FDA Filing
PHILADELPHIA, PA — Century Therapeutics (Nasdaq: IPSC) reported new preclinical data supporting its experimental type 1 diabetes therapy CNTY-813, as the biotechnology company works toward a planned Investigational New Drug …
Century Therapeutics Advances Diabetes Cell Therapy Toward 2026 FDA Filing Read More